Literature DB >> 19211641

Comparative analysis of oncogenic properties and nuclear factor-kappaB activity of latent membrane protein 1 natural variants from Hodgkin's lymphoma's Reed-Sternberg cells and normal B-lymphocytes.

Nathalie Faumont1, Aurélie Chanut, Alan Benard, Nadine Cogne, Georges Delsol, Jean Feuillard, Fabienne Meggetto.   

Abstract

BACKGROUND: In Epstein-Barr virus-associated Hodgkin's lymphomas, neoplastic Reed-Sternberg cells and surrounding non-tumor B-cells contain different variants of the LMP1-BNLF1 oncogene. In this study, we raised the question of functional properties of latent membrane protein 1 (LMP1) natural variants from both Reed-Sternberg and non-tumor B-cells. DESIGN AND METHODS: Twelve LMP1 natural variants from Reed-Sternberg cells, non-tumor B-cells of Hodgkin's lymphomas and from B-cells of benign reactive lymph nodes were cloned, sequenced and stably transfected in murine recombinant interleukin-3-dependent Ba/F3 cells to search for relationships between LMP1 cellular origin and oncogenic properties as well as nuclear factor-kappaB activation, and apoptosis protection.
RESULTS: LMP1 variants of Reed-Sternberg cell origin were often associated with increased mutation rate and with recurrent genetic events, such as del15bp associated with S to N replacement at codon 309, and four substitutions I85L, F106Y, I122L, and M129I. Oncogenic potential (growth factor-independence plus clonogenicity) was consistently associated with LMP1 variants from Reed-Sternberg cells, but inconstantly for LMP1-variants from non-tumor B-cells. Analysis of LMP1 variants from both normal B-cells and Reed-Sternberg cells indicates that protection against apoptosis through activation of nuclear factor-kappaB - whatever the cellular origin of LMP1 - was maintained intact, regardless of the mutational pattern.
CONCLUSIONS: Taken together, our results demonstrate that preserved nuclear factor-kappaB activity and protection against apoptosis would be the minimal prerequisites for all LMP1 natural variants from both normal and tumor cells in Hodgkin's lymphomas, and that oncogenic potential would constitute an additional feature for LMP1 natural variants in Reed-Sternberg cells.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19211641      PMCID: PMC2649341          DOI: 10.3324/haematol.13269

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  44 in total

Review 1.  Nuclear factor-kappaB: a friend or a foe in cancer?

Authors:  Shishir Shishodia; Bharat B Aggarwal
Journal:  Biochem Pharmacol       Date:  2004-09-15       Impact factor: 5.858

2.  Epstein-Barr virus: transformation, cytopathic changes, and viral antigens in squirrel monkey and marmoset leukocytes.

Authors:  G Miller; T Shope; H Lisco; D Stitt; M Lipman
Journal:  Proc Natl Acad Sci U S A       Date:  1972-02       Impact factor: 11.205

Review 3.  Epstein-barr virus transformation: involvement of latent membrane protein 1-mediated activation of NF-kappaB.

Authors:  E D Cahir McFarland; K M Izumi; G Mosialos
Journal:  Oncogene       Date:  1999-11-22       Impact factor: 9.867

4.  Nuclear factor-kappaB activation is involved in LMP1-mediated transformation and tumorigenesis of rat-1 fibroblasts.

Authors:  Z He; B Xin; X Yang; C Chan; L Cao
Journal:  Cancer Res       Date:  2000-04-01       Impact factor: 12.701

Review 5.  Epstein-Barr virus: 40 years on.

Authors:  Lawrence S Young; Alan B Rickinson
Journal:  Nat Rev Cancer       Date:  2004-10       Impact factor: 60.716

6.  The transmembrane domains of the EBV-encoded latent membrane protein 1 (LMP1) variant CAO regulate enhanced signalling activity.

Authors:  S M Blake; A G Eliopoulos; C W Dawson; L S Young
Journal:  Virology       Date:  2001-04-10       Impact factor: 3.616

Review 7.  JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis.

Authors:  L S Steelman; S C Pohnert; J G Shelton; R A Franklin; F E Bertrand; J A McCubrey
Journal:  Leukemia       Date:  2004-02       Impact factor: 11.528

8.  Il-3-dependent mouse clones that express B-220 surface antigen, contain Ig genes in germ-line configuration, and generate B lymphocytes in vivo.

Authors:  R Palacios; M Steinmetz
Journal:  Cell       Date:  1985-07       Impact factor: 41.582

9.  Potential selection of LMP1 variants in nasopharyngeal carcinoma.

Authors:  Rachel H Edwards; Diane Sitki-Green; Dominic T Moore; Nancy Raab-Traub
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

10.  In Hodgkin's disease Reed-Sternberg cells and normal B-lymphocytes are infected by related Epstein-Barr virus strains.

Authors:  Nathalie Faumont; Pascal Trempat; Pierre Brousset; Georges Delsol; Fabienne Meggetto
Journal:  Virus Res       Date:  2004-05       Impact factor: 3.303

View more
  4 in total

1.  RelA and RelB cross-talk and function in Epstein-Barr virus transformed B cells.

Authors:  A Chanut; F Duguet; A Marfak; A David; B Petit; M Parrens; S Durand-Panteix; M Boulin-Deveza; N Gachard; I Youlyouz-Marfak; D Bordessoule; J Feuillard; N Faumont
Journal:  Leukemia       Date:  2013-09-23       Impact factor: 11.528

2.  Epstein-Barr virus latent membrane protein 1 genetic variability in peripheral blood B cells and oropharyngeal fluids.

Authors:  Nicholas Renzette; Mohan Somasundaran; Frank Brewster; James Coderre; Eric R Weiss; Margaret McManus; Thomas Greenough; Barbara Tabak; Manuel Garber; Timothy F Kowalik; Katherine Luzuriaga
Journal:  J Virol       Date:  2014-01-15       Impact factor: 5.103

3.  Genomic Instability: The Driving Force behind Refractory/Relapsing Hodgkin's Lymphoma.

Authors:  Hans Knecht; Christiaan Righolt; Sabine Mai
Journal:  Cancers (Basel)       Date:  2013-06-05       Impact factor: 6.639

4.  Difference in cytokine production and cell cycle progression induced by Epstein-Barr virus Lmp1 deletion variants in Kmh2, a Hodgkin lymphoma cell line.

Authors:  Charlotte Sueur; Julien Lupo; Philippe Mas; Patrice Morand; Véronique Boyer
Journal:  Virol J       Date:  2014-05-19       Impact factor: 4.099

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.